PHI applies for listing on OTCQB in the United States
Phase Holographic Imaging (PHI) is pursuing a dual listing on the US-based OTCQB Venture Market (“OTCQB”) to provide US-based investors with the ability to invest in PHI. PHI aims to solidify further its presence in the major US market and within regenerative medicine, a rapidly evolving field, spearheaded by the United States globally. The application process has been initiated, and PHI expects to receive approval in the third quarter of 2024.
PHI's CEO, Patrik Eschricht, comments:
"We are excited about the potential of trading on the OTCQB as it offers our current and prospective shareholders an additional platform for trading our shares. For PHI, this dual listing would provide greater exposure to the major US market, making it easier for investors to invest in our innovative solutions and our vision for regenerative medicine. We believe this step will drive increased liquidity, enhance shareholder value, and support PHI's continued growth.”
PHI is currently trading on the Spotlight Stock Market under the ticker PHI. The dual listing on the OTCQB would simplify the process for international investors to invest in PHI and allow US-based investors to trade PHI shares easily. PHI has started the application process and anticipates receiving approval in the third quarter of 2024.
For additional information, please contact:
Lisa Bodily
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.